Mölnlycke Health Care is Expanding its Wound Care Manufacturing Facility

Swedish medtech firm Mölnlycke Health Care has begun a major expansion to its wound care manufacturing capacity in Brunswick, Me., as part of the company’s $135 million effort to significantly increase its U.S. production capabilities. 

“This expansion is a bold step forward for Mölnlycke in the U.S. It reinforces our mission to free patients and caregivers from the burden of wounds, strengthens supply resilience, and helps us to deliver high-quality wound care solutions faster, smarter, and more sustainably,” Mölnlycke Health Care CEO Zlatko Rihter said. “I’m proud to mark this milestone for Mölnlycke, for Maine, and for the future of medtech.”  

The expansion is part of Mölnlycke’s strategic commitment to localize production and meet growing demand from U.S. healthcare providers. The state-of-the-art facility will support Mölnlycke’s long-term sustainability goals by using renewable energy solutions, including wind and solar power, and streamlined logistics. It will also feature advanced machinery sourced from U.S. suppliers. 

Over the next five years, the investment will create new job opportunities, increasing Mölnlycke’s workforce in Maine by approximately 10%, and will engage local contractors and suppliers. The Brunswick expansion is designed to eventually help more U.S. patients benefit from Mölnlycke’s wound care products. 

“Today isn’t just about breaking ground. It’s about being bold, embracing partnerships and leading with passion,” stated Chris Biddle, general manager of U.S. Manufacturing, Wound Care, at Mölnlycke. “Thank you to everyone who helped bring this vision to reality. The expansion is a win for Mölnlycke, for the local community and, ultimately, for the patients we serve.”  

Senior federal and state lawmakers, including U.S. Sen. Angus King, and Maine Gov. Janet Mills offered their support for the investment. 

“Since coming to Brunswick, Mölnlycke has joined dozens of other businesses in helping turn Brunswick Landing into a thriving economic engine for our state,” Gov. Mills stated. “I am proud our new Dirigo Business Incentive Program will help Mölnlycke make its biggest investment yet in Maine, to meet rising global demand for its medical products used in more than 100 countries around the world. This expansion celebrates Mölnlycke’s rise as a pioneering developer of medical products and demonstrates that Maine is a tremendous place for doing business.”

Mölnlycke’s expansion project is supported by the Governor’s Dirigo Business Incentive Program. This year, more than 90 businesses statewide have been approved for the program and are collectively planning for an estimated $800 million in capital investments in the Pine Tree State over the next five years.

Gov. Mills initiated the Dirigo Business Incentive program in April 2023 to provide tax credits to businesses for worker training and capital investment—an approach to help address Maine’s labor shortage and attract new businesses to the state. After earning bipartisan support from the Legislature, the program was included in the budget the governor signed into law in 2023.

Mölnlycke Health Care is a medech company specializing in solutions for wound care and surgical procedures.